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Pathway Targets to Explore in the Treatment of Small Cell
and Large Cell Lung Cancers
Anoor Paripati, MBBS,* Chris Kingsley, PhD,† and Glen J. Weiss, MD*†
Introduction:With low 5-year survival rates and little progress in
therapy, improvements in therapeutic strategies for the treatment
of small cell lung cancer (SCLC) and large cell lung cancer
(LCC) are warranted. We hypothesized that different SCLC and
LCC microarray data sets will share commonly perturbed path-
ways leading to the identification of new targets for therapeutic
development.
Methods: Per gene mean expression fold change ratios were calcu-
lated from four publicly available microarray data sets consisting of
a total of 113 profiled samples. This was followed by mapping of
differentially expressed genes into functionally annotated biologic
pathways using Ingenuity pathway analysis software. Common
pathways containing genes whose expression levels differed be-
tween phenotypic classes defined by histology and gender were
determined.
Results: Several significant common pathways overlapping these
data sets were identified in silico. One of which, the Wnt/-catenin
signaling pathway, is targeted by agents such as vorinostat and
dasatinib, which are currently under exploration in SCLC trials. The
remaining pathways are targeted by several drugs developed or
under development in cancer therapeutics.
Conclusion: This in silico pathway exploration in SCLC and LCC
holds promise. Additional expression profiling of SCLC and LCC
cases would likely add to the knowledge base. Further investigation
into identified targets is warranted.
Key Words: Gene expression profiling, Small cell lung cancer,
Large cell lung cancer, Pathway analysis, In silico, Treatment.
(J Thorac Oncol. 2009;4: 1313–1321)
Small cell lung cancer (SCLC) and large cell lung cancer(LCC) are subgroups of lung carcinomas. SCLC repre-
sents approximately 10%1 and LCC represents approxi-
mately 1 to 3% of all lung cancer cases,1,2 of which
approximately 60 to 70% present with extensive/advanced
disease at diagnosis.2,3 In the last few decades, there have
been minimal improvements in the treatment of extensive-
stage SCLC, with treatment primarily consisting of a
platinum agent with either etoposide or irinotecan.4 The
5-year survival rate for SCLC is just 5% according to the
1973–2003 Surveillance Epidemiology and End Results
registry. Comparatively, as a whole, LCC has a better
prognosis with a 5-year survival rate of 15 to 57%.2,5,6
There are up to five distinct variants of LCC according to
the World Health Organization organization,7 with the two
main variants being large cell neuroendocrine carcinoma
(LCNEC) and basaloid. LCNEC is primarily distinguished
by its neuroendocrine morphology and neuroendocrine
marker immunohistochemical staining, in contrast to the
basaloid variant, which differs in tumor cell size, nuclear
features, and lack of neuroendocrine immunohistochemi-
cal staining.7 Matched for stage, there is no distinct sur-
vival advantage between SCLC and LCNEC.7 Although
there are molecularly different features that distinguish
between the variants of LCC and other lung cancer sub-
types, LCC is commonly lumped together in the treatment
strategy for non-small cell lung cancer (NSCLC), with
appreciation for its inferior prognosis to other NSCLC.
New approaches for target discovery can yield improved
strategies for tailored therapy. Mining already available
gene expression microarray data sets for shared common
pathways may lead to the identification of new and
possibly unrealized targets in the treatment of SCLC
and LCC.
METHODS
Microarray data sets from the Japanese Foundation for
Cancer Research, Tokyo, Japan (Tokyo)8 were generated
using custom spotted microarrays and downloaded as text
files prenormalized using locally weighted scatterplot
smoothing normalization. Microarray data sets from the UT
Southwestern Medical Center, Dallas, Texas (Dallas),9 were
generated using the Affymetrix GeneChip Human Genome
U133 Array Set and downloaded as text files prenormalized
using MAS 5.0 and global scaling. Microarray data sets from
the University of Duesseldorf, Germany (Duesseldorf)10 were
generated using the Affymetrix GeneChip Human HG-Focus
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Target Array, downloaded as raw Affymetrix.cel files and nor-
malized using the Robust Multichip Average method11 as imple-
mented in the Affymetrix Expression Console v1.1. Microarray
data sets from Chiba University, Chiba, China (Chiba)12 were
generated using the Hitachisoft AceGene Human Oligo Chip 30K
Subset A array and downloaded as text files prenormalized by
DNASIS array software (Hitachi Software Engineering).
For all data sets, SCLC (including SCLC cell lines),
LCC (including LCC cell lines), and benign lung tissue
(including benign lung epithelial cell lines) were evaluated
(where available), and per gene mean mRNA expression fold
change ratios were separately calculated from the selected
samples of each data set. When the appropriate clinical
annotations were available, fold changes were calculated for
SCLC versus LCC, SCLC versus benign lung, LCC versus
benign lung, and male versus female. Further details on
methods applied to microarray analysis were entered into
Sweave (http://www.stat.uni-muenchen.de/leisch/Sweave/,
Supplementary Methods it is also available as Supplementary
Digital Content 1, http://links.lww.com/JTO/A9), and all data
set files can be accessed without password (ftp.tgen.org, username
is anonymous@gwlcu).
Fold changes greater than 2 or less than 0.5 were
analyzed in a functional annotation and pathway database
using Ingenuity pathway analysis (IPA).13 Common path-
ways significantly perturbed when comparing expression
profiles were identified. Canonical pathways were interro-
gated, and p values from all performed hypothesis tests
were adjusted by the method of Benjamini and Hochberg to
estimate the False Discovery Rate (FDR).14 Pathways were
recorded if their estimated FDRwas less than 0.05. When two or
more institutions shared significant canonical IPA pathway re-
sults by category, the pathway was annotated as a “common
pathway.” Common pathways were interrogated for the pres-
ence of known oncogenes and drugs known to target these
oncogenes.
RESULTS
Clinical characteristics of profiled samples (n  113)
are summarized in Table 1. Age, gender, ethnicity, and
histology were included where available. The Dallas data set
comprised cell lines only, whereas the Duesseldorf and Chiba
data sets consisted of less than 15 samples each.
Using IPA, several common pathways were identified
in silico as significantly differentially expressed among these
data sets. Table 2 lists the pathways with an estimated FDR
less than 5% among the data sets. Table 3 lists the common
pathways shared among the data sets. In the SCLC versus
LCC comparison, there were six common pathways shared
by at least two data sets—Amyotrophic Lateral Sclerosis
Signaling, cell cycle: G2/M DNA Damage Checkpoint Reg-
ulation, Glucocorticoid Receptor Signaling, Glutamate Re-
ceptor Signaling, p53 Signaling, and Wnt/-catenin Signaling
pathways.
Possible drug targets in the Amyotrophic Lateral
Sclerosis Signaling pathway include AKT3 and Bcl-2 for
which enzastaurin and oblimersen could be potential
agents, respectively (Supplementary Digital Content 2, Table 1,
http://links.lww.com/JTO/A10). PI3K and vascular endothelial
growth factor (VEGF) are also listed as potential targets for
which several agents are under development. Bevacizumab is a
monoclonal antibody to VEGF ligand and is approved in several
cancers, including NSCLC. The cell cycle: G2/MDNADamage
Checkpoint Regulation pathway includes Cdc2 and CDK7 for
which flavopiridol could be a potential agent (Supplementary
Digital Content 2, Table 2, http://links.lww.com/JTO/A10). Topo-
TABLE 1. Clinical Characteristics of Analyzed Specimens
Clinical Characteristic
Tokyo Data Set
(N  65)
Dallas Data Set
(N  31)
Duesseldorf Data Set
(N  14)
Chiba Data Set
(N  13)
Age (range) N/A 11–67a 39–74 52–74
Gender
Female/male N/A 6/25 7/7 1/12
Ethnicity
White — 84% 100% —
Asian 100% — — 100%
African American — 13% — —
Histology
LCC 20 — — 10
SCLC 15 — 9 3
LCC cell line — 6 — —
SCLC cell line 11 22 — —
Benign lung tissue 19 — 5 —
Benign lung cell line — 3 — —
Array platform Custom spotted
array
Affymetrix GeneChip Human
Genome U133 array
Affymetrix GeneChip Human
HG-Focus Target array
Hitachisoft AceGene Human
Oligo Chip 30K Subset
A array
The 11 yr old is the age of the tissue donor for a benign lung cell line.
LCC, large cell lung cancer; SCLC, small cell lung cancer; N/A, not available.
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TABLE 2. Significant Pathways by Clinical Characteristics
SCLC vs. benign lung pathway (comparison unavailable in Chiba data set)
None (1, 2)
Pyrimidine metabolism (3)
Role of BRCA1 in DNA damage response (3)
LCC vs. benign lung pathway (comparison unavailable in Chiba and
Duesseldorf data sets)
None (1, 2)
SCLC vs. LCC pathway (comparison unavailable in Duesseldorf data set)
None (4)
Acute phase response signaling (1)
Actin cytoskeleton signaling (2)
Amyloid processing (2)
Amyotrophic lateral sclerosis signaling (1, 2)
Androgen and estrogen metabolism (2)
Axonal guidance signaling (2)
Butanoate metabolism (2)
Calcium signaling (2)
cAMP-mediated signaling (2)
Cardiac -adrenergic signaling (2)
Cell cycle: G2/M DNA damage checkpoint regulation (1, 2)
Chemokine signaling (2)
Dopamine receptor signaling (2)
Ephrin receptor signaling (2)
Fatty acid metabolism (2)
Fc Epsilon RI signaling (2)
FXR/RXR activation (1)
GABA receptor signaling (2)
Glucocorticoid receptor signaling (1, 2)
Glutamate receptor signaling (1, 2)
Glycerolipid metabolism (2)
Glycerophospholipid metabolism (2)
Glycine, serine, and threonine metabolism (2)
Glycolysis/gluconeogenesis (2)
G-Protein coupled receptor signaling (2)
Huntington’s disease signaling (2)
Hypoxia signaling in the cardiovascular system (1)
IL-2 signaling (2)
IL-6 signaling (1)
Inositol phosphate metabolism (2)
Insulin receptor signaling (2)
JAK/stat signaling (1)
Leukocyte extravasation signaling (2)
Natural killer cell signaling (2)
Nitric oxide signaling in the cardiovascular system (2)
p53 signaling (1, 2)
Phospholipid degradation (2)
Phototransduction pathway (2)
PI3K/AKT signaling (1)
Protein ubiquitination pathway (2)
PTEN signaling (2)
Purine metabolism (2)
Pyrimidine metabolism (2)
RAR activation (2)
Role of BRCA1 in DNA damage response (2)
SAPK/JNK signaling (2)
Serotonin receptor signaling (2)
Sonic Hedgehog signaling (2)
Synaptic long term depression (2)
Synaptic long term potentiation (2)
Synthesis and degradation of ketone bodies (2)
T-cell receptor signaling (2)
Tight junction signaling (2)
TR/RXR activation (2)
Tryptophan metabolism (2)
Valine, leucine and isoleucine degradation (2)
Wnt/-catenin signaling (1, 2)
-Adrenergic signaling (2)
-alanine metabolism (2)
SCLC male vs. female pathway (comparison unavailable in Tokyo and
Chiba data sets)
12-3-3-mediated signaling (2)
a-Adrenergic signaling (2)
Actin cytoskeleton signaling (2)
Acute phase response signaling (2)
Alanine and aspartate metabolism (2)
Aminoacyl-tRNA biosynthesis (2)
Aminosugars metabolism (2)
Amyotrophic lateral sclerosis signaling (2)
Androgen and estrogen metabolism (2)
Antigen presentation pathway (2)
Apoptosis signaling (2)
Arachidonic acid metabolism (2)
Arginine and proline metabolism (2)
Aryl hydrocarbon receptor signaling (2)
Ascorbate and aldarate metabolism (2)
Axonal guidance signaling (2)
B-cell receptor signaling (2)
Bile acid biosynthesis (2)
BMP signaling pathway (2)
Butanoate metabolism (2)
C21-steroid hormone metabolism (2)
Calcium signaling (2)
cAMP-mediated signaling (2)
Cardiac ß-adrenergic signaling (2)
Cell cycle: G1/S checkpoint regulation (2)
Ceramide signaling (2)
Chemokine signaling (2)
Chondroitin sulfate biosynthesis (2)
Citrate cycle (2)
Cyanoamino acid metabolism (2)
Cysteine metabolism (2)
D-glutamine and D-glutamate metabolism (2)
Dopamine receptor signaling (2)
EGF signaling (2)
Eicosanoid signaling (2)
Ephrin receptor signaling (2)
ERK/MAPK signaling (2)
Erythropoietin signaling (2)
Estrogen receptor signaling (2)
Fatty acid elongation in mitochondria (2)
Fatty acid metabolism (2)
Eicosanoid signaling (2)
Ephrin receptor signaling (2)
ERK/MAPK signaling (2)
Erythropoietin signaling (2)
Estrogen receptor signaling (2)
Fatty acid elongation in mitochondria (2)
(Continued)
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TABLE 2. (Continued)
Fatty acid metabolism (2)
Fc epsilon RI signaling (2)
FGF signaling (2)
FXR/RXR activation (2)
GABA receptor signaling (2)
Glucocorticoid receptor signaling (2)
Glutamate metabolism (2)
Glutamate receptor signaling (2)
Glutathione metabolism (2)
Glycerolipid metabolism (2)
Glycerophospholipid metabolism (2)
Glycine, serine and threonine metabolism (2)
Glycolysis/gluconeogenesis (2)
Glycosaminoglycan degradation (2)
Glycosphingolipid biosynthesis—ganglioseries (2)
Glycosphingolipid biosynthesis—globoseries (2)
GM-CSF signaling (2)
G-Protein coupled receptor signaling (2)
Hepatic cholestasis (2)
Hepatic fibrosis/hepatic stellate cell activation (2)
Histidine metabolism (2)
Huntington’s disease signaling (2)
Hypoxia signaling in the cardiovascular system (2)
IGF-1 signaling (2)
IL-10 signaling (2)
IL-2 signaling (2)
IL-2 signaling (2)
IL-6 signaling (2)
Inositol phosphate metabolism (2)
Insulin receptor signaling (2)
Integrin signaling (2)
Interferon signaling (2)
JAK/Stat signaling (2)
Keratan sulfate biosynthesis (2)
Leukocyte extravasation signaling (2)
Linoleic acid metabolism (2)
LPS/IL-1 mediated inhibition of RXR function (2)
LXR/RXR activation (2)
Lysine biosynthesis (2)
Lysine degradation (2)
Metabolism of xenobiotics by cytochrome P250 (3, 2)
Methane metabolism (2)
Natural killer cell signaling (2)
Neuregulin signaling (2)
Neurotrophin/TRK signaling (2)
NF-kB signaling (2)
N-glycan biosynthesis (2)
N-glycan degradation (2)
Nicotinate and nicotinamide metabolism (2)
Nitric oxide signaling in the cardiovascular system (2)
Nitrogen metabolism (2)
Notch signaling (2)
NRF2-mediated oxidative stress response (2)
Nucleotide excision repair pathway (2)
O-glycan biosynthesis (2)
Oxidative phosphorylation (2)
p38 MAPK signaling (2)
p53 signaling (2)
Pantothenate and CoA biosynthesis (2)
PDGF signaling (2)
Pentose and glucuronate interconversions (2)
Pentose phosphate pathway (2)
Phenylalanine metabolism (2)
Phospholipid degradation (2)
Phototransduction pathway (2)
PI3K/AKT signaling (2)
PPAR signaling (2)
PPARa/RXRa activation (2)
Propanoate metabolism (2)
Protein ubiquitination pathway (2)
PTEN signaling (2)
Purine metabolism (2)
PXR/RXR activation (2)
Pyrimidine metabolism (2)
Pyruvate metabolism (2)
RAR activation (2)
Regulation of actin-based motility by rho (2)
Retinol metabolism (2, 3)
Riboflavin metabolism (2)
Role of BRCA1 in DNA damage response (2)
SAPK/JNK signaling (2)
Selenoamino acid metabolism (2)
Serotonin receptor signaling (2)
Sonic Hedgehog signaling (2)
Sphingolipid metabolism (2)
ß-alanine metabolism (2)
Starch and sucrose metabolism (2)
Stilbene, coumarine and lignin biosynthesis (2)
Synaptic long-term depression (2)
Synaptic long-term potentiation (2)
T-cell receptor signaling (2)
TGF-ß signaling (2)
Tight junction signaling (2)
TR/RXR activation (2)
Tryptophan metabolism (2)
Tyrosine metabolism (2)
Urea cycle and metabolism of amino groups (2)
Valine, leucine and isoleucine degradation (2)
VDR/RXR activation (2)
VEGF signaling (2)
Wnt/ß-catenin signaling (2)
Xenobiotic metabolism signaling (2)
None, no significant pathways found in the identified data set; 1, Tokyo; 2, Dallas;
3, Duesseldorf; 4, Chiba.
LCC, large cell lung cancer; SCLC, small cell lung cancer; IL, interleukin; BRCA1,
breast cancer 1, early onset; cAMP, cyclic adenosine monophosphate; FXR/RXR, farnesoid
X receptor/retinoid X receptor; GABA, gamma-aminobutyric acid; JAK, janus kinase;
AKT, v-akt murine thymoma viral oncogene; PTEN, phosphatase and tensin homolog;
RAR, retinoic acid receptor; SAPK, stress-activated protein kinase; JNK, c-Jun n-terminal
kinases; TR/RXR, thyroid hormone receptor/retinoid Xx receptor; BMP, bone morphoge-
netic proteins; EGF, epidermal growth factor; ERK/MAPK, extracellular signal-regulated
kinase/mitogen-activated protein kinase; FGF, fibroblast growth factor; GM-CSF, granulo-
cyte macrophage colony stimulating factor; IGF-1, insulin-like growth factor 1; LPS,
lipopolysaccharide; RXR, retinoid X receptor; LXR, liver X receptor; TRK, Tyrosine
Kinase; NRF2, basic leucine zipper (b-Zip) transcription factor, NF-E2-related factor 2;
PGDF, Platelet-Derived Growth Factor; PPAR, Peroxisome Proliferator Activated Recep-
tor; PPARa/RXRa, peroxisome proliferator-activated receptor-alpha/retinoid X receptor-
alpha; TGF-, transforming growth factor-beta; VDR, vitamin D receptor; VEGF, vascular
endothelial growth factor.
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isomerase II is a target for which etoposide and doxorubicin
are part of the known SCLC treatment armamentarium. Plk1
is also a potential target with two new agents recently
completing phase I study.15,16 Possible targets in the Glu-
cocorticoid Receptor Signaling pathway include the androgen
receptor, estrogen receptor, and tumor necrosis factor-,
which can be targeted by bicalutamide or flutamide; tamoxifen
or aromatase inhibitors; and thalidomide, respectively (Supplemen-
tary Table 3, http://links.lww.com/JTO/A10). Fasoracetam, a noot-
ropic agent, under clinical investigation as a cognitive enhancer, is
a potential drug for the Glutamate Receptor Signaling pathway
targeting glutamate receptor metabotropic 1 to 8 (Supplementary
Digital Content 2, Table 4, http://links.lww.com/JTO/A10). The
p53 Signaling pathway includes Bcl-2, v-akt murine thymoma viral
oncogene, and GSK3, CDK2 and CDK4, and HDAC for which
drugs such as oblimersen, enzaustarin, flavopiridol, and vorinos-
tat, respectively, could be potential agents (Supplementary Dig-
ital Content 2, Table 5, http://links.lww.com/JTO/A10). In ad-
dition to enzaustarin, vorinostat (currently under evaluation in
combination with carboplatin and etoposide in extensive-stage
SCLC) and dasatinib (currently under evaluation in chemosen-
sitive relapsed SCLC) could be effective agents for the HDAC1
and Src targets, which are members of the Wnt/-catenin sig-
naling pathway (Supplementary Digital Content 2, Table 6,
http://links.lww.com/JTO/A10). Key targets in Amyotrophic
Lateral Sclerosis Signaling, cell cycle: G2/M DNA Damage
Checkpoint Regulation, p53 Signaling and Wnt/-catenin Sig-
naling pathways, and their respective potential targeting drugs
are included in Figures 1 to 4, respectively.
No significant pathways were identified in any of the
clinical annotation comparisons in the Chiba data set,
likely explained by the small sample size available for
analysis. In the SCLC versus benign lung comparison, only the
Duesseldorf data set showed significantly affected pathways by
IPA, and these were the Pyrimidine metabolism and Role of
breast cancer 1, early onset in DNA Damage Response path-
ways. However, no potential drug targets are currently under
investigation in cancer trials. In the LCC versus benign lung
FIGURE 1. Amyotrophic Lateral Sclerosis Signaling pathway and potential targeting drugs
This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name)
connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are
depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supple-
mentary Table 1 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of In-
genuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com) and printed with permission.
TABLE 3. Pathways Ranked by Commonalities
SCLC vs. LCC
2 of 3
Amyotrophic lateral sclerosis signaling (1, 2)
Cell cycle: G2/M DNA damage checkpoint regulation (1, 2)
Glucocorticoid receptor signaling (1, 2)
Glutamate receptor signaling (1, 2)
p53 signaling (1, 2)
Wnt/-catenin signaling (1, 2)
SCLC male vs. female
2 of 2
Metabolism of xenobiotics by cytochrome P450 (2, 3)
Retinol metabolism (2, 3)
1, Tokyo; 2, Dallas; 3, Duesseldorf.
SCLC, small cell lung cancer; LCC, large cell lung cancer.
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comparison, there were no statistically significant affected path-
ways by IPA.
In the male versus female comparison, only the SCLC
histologic class in the data sets had sufficient sample numbers
for IPA. Less than 1% of the differentially expressed gene
probes mapped to the Y chromosome, suggesting other genes
are the drivers for these differences. Common pathways
identified include Metabolism of Xenobiotics by Cytochrome
P450 and Retinol Metabolism. It is not surprising that by
gender comparison, aromatase inhibitors are identified as a
potential drug target, identified in the former pathway. Inter-
estingly, disulfiram is a potential target in the latter pathway,
and this commonly used drug for treating substance depen-
dence has been studied in solid tumors as a single agent and
in combination therapy.17
DISCUSSION
When we first considered pursuing this study, we
were unsure whether sufficient numbers of SCLC and LCC
samples existed in publicly available gene expression data
sets to derive any meaningful pathway commonalities or
targets. Fortunately, several significant pathways were
identified by IPA, and common pathways were found
across multiple data sets. In fact, identified targets within
these common pathways include drug targets that have
previously been reported or studied in lung cancer, partic-
ularly SCLC. IPA applied to the four data sets revealed
potentially new drug targets that may be considered by
investigators for further study. To embark on this path to
target these potential candidates, investigators must first
assess the identified target’s function as a driver of malig-
nant progression in these tumors.
Using publicly available SCLC and LCC gene ex-
pression data sets, we identified in silico several pathways
that are perturbed in various clinical comparisons in at
least two data sets (Table 3). Confirmation of the in silico
approach for identifying potential targets to consider, we
identified a few had similar targeting drugs in these com-
mon pathways including oblimersen, enzastaurin, fla-
vopiridol, and vorinostat. Several of these agents were
under clinical evaluation in SCLC including oblimersen,
enzaustarin, bevacizumab, BI 2536 (PLK1 inhibitor), tha-
lidomide, and dasatinib.17 Two agents, etoposide and
doxorubicin are already part of well-established treatment
regimens for SCLC.18
A search of the literature for the prevalence of these
pathway targets in clinical SCLC samples is scant, and no
relevant publications on their prevalence in clinical LCC
samples could be identified. In a small series, Bcl-2 ex-
pression by immunohistochemistry was present in 68% (9
of 13) SCLC.19 Compared with healthy control subjects,
serum VEGF in patients with SCLC (n  38) were signif-
icantly elevated (p  0.001).20
This study is limited by the number of available data
sets and in silico analysis. With routine gene expression
analysis, differentiating classifiers can be identified. The
FIGURE 2. Cell cycle: G2/M DNA Damage Checkpoint Regulation pathway and potential targeting drugs
This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name)
connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are
depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supple-
mentary Table 2 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of In-
genuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com) and printed with permission.
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application of IPA analysis and FDR correction incorpo-
rates more stringent identification of notable classifiers and
pathways. Notably, this was demonstrated in the compar-
ison of LCC with benign tissue or benign cell lines. There
were 2964 of 40,369 and 13,644 of 44,592 gene probes
from the Tokyo and Dallas data sets, respectively. After
imputation in IPA and FDR correction, there were no
significantly perturbed pathways.
Further preclinical evaluation, including target func-
tionality studies, should be considered by other interested
investigators. With confirmation of promising preclinical
work, it is feasible that clinical trial investigation of agents in
the treatment of SCLC and/or LCC may lead to better therapy
to patients with these cancers. Ideally, greater confidence in
the validity of these targets and pathway analysis in SCLC
and LCC would be strengthened if these results could be
validated in preclinical studies or if additional gene expres-
sion data sets including these cancers, with detailed annota-
tion including the subtype variant, were part of the public
domain.
CONCLUSION
Utilization of IPA to explore common pathways in
gene expression data sets may lead to new drugs and
targets for the treatment of SCLC and/or LCC. This in
silico pathway exploration in SCLC and LCC holds prom-
ise. Further investigation into identified targets is war-
ranted. Additional expression profiling of SCLC and LCC
can add to the field.
FIGURE 3. p53 Signaling pathway and potential targeting drugs
This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name)
connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are
depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supple-
mentary Table 5 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of In-
genuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com) and printed with permission.
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